

APPENDIX A

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Claims:

3. A method for determining whether ~~a taxane~~ TAXOL cannot be used to reduce the growth of cancer cells, comprising the steps of:

- a) obtaining a sample of cancer cells;
- b) determining whether said cancer cells express one or more genes selected from the group consisting of the resistance genes identified in Tables 8A, 9A, 9B, 9C, 9D, 10A, and 11A; and
- c) identifying that ~~an agent~~ TAXOL cannot be used to reduce the growth of said cancer cells when one or more of said genes is expressed by said cancer cells.

18. A method for determining whether ~~a taxane~~ TAXOL cannot be used to reduce the growth of cancer cells, comprising the steps of:

- a) obtaining a sample of cancer cells;
- b) exposing the cancer cells ~~to one or more test agents~~ TAXOL;
- c) determining the level of expression in the cancer cells of one or more genes selected from the group consisting of the resistance genes identified in Tables 8A, 9A, 9B, 9C, 9D, 10A, and 11A in the sample exposed to ~~the agent~~ TAXOL and in a sample of cancer cells that is not exposed to ~~the agent~~ TAXOL; and
- d) identifying that ~~an agent~~ TAXOL cannot be used to reduce the growth of said cancer cells when the expression of one or more of said genes is increased in the presence of ~~said agent~~ TAXOL.

32. A method for determining whether treatment with ~~a taxane anti-cancer agent~~ TAXOL should be continued in a cancer patient, comprising the steps of:

- a) obtaining two or more samples comprising cancer cells from a patient during the course of ~~anti-cancer agent~~ TAXOL treatment;

b) determining the level of expression in the cancer cells of one or more genes selected from the group consisting of the resistance genes identified in Tables 8A, 9A, 9B, 9C, 9D, 10A, and 11A in the two or more samples; and

c) discontinuing treatment when the expression level of one or more of said genes increases during the course of treatment.

33. A method for determining whether treatment with ~~a taxane anti-cancer agent~~ TAXOL should be continued in a cancer patient, comprising the steps of:

a) obtaining two or more samples comprising cancer cells from a patient during the course of ~~anti-cancer agent~~ TAXOL treatment;

b) determining the level of expression in the cancer cells of one or more genes selected from the group consisting of the resistance genes identified in Tables 8A, 9A, 9B, 9C, 9D, 10A, and 11A in the two or more samples; and

c) continuing treatment when the expression level of one or more of said genes does not increase during the course of treatment.